Free Trial

Penumbra Q3 2024 Earnings Report

Penumbra logo
$264.08 +1.77 (+0.67%)
As of 01/17/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Penumbra EPS Results

Actual EPS
$0.85
Consensus EPS
$0.69
Beat/Miss
Beat by +$0.16
One Year Ago EPS
$0.67

Penumbra Revenue Results

Actual Revenue
$301.04 million
Expected Revenue
$297.36 million
Beat/Miss
Beat by +$3.68 million
YoY Revenue Growth
+11.10%

Penumbra Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Penumbra Earnings Headlines

Peering Into Penumbra's Recent Short Interest
Wells Fargo Sticks to Its Buy Rating for Penumbra (PEN)
Grab This Altcoin Before Trump's Crypto Announcement
The #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of a lifetime!
Penumbra (PEN) Gets a Hold from Citi
See More Penumbra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email.

About Penumbra

Penumbra (NYSE:PEN), together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

View Penumbra Profile

More Earnings Resources from MarketBeat